ALX Oncology

📍 South San Francisco, United States🗓 Founded 2015👥 67 employees💰 Last funded Feb 2020
Biotechnology🌐 alxoncology.com
Website LinkedIn
ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. ALX Oncology’s lead product candidate, evorpacept (also known as ALX148), is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. Evorpacept has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents.
2
Total investors
1
Early stage
1
Mid stage
0
Late stage
2015
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Early stage· 1
Jason Lettmann
Jason Lettmann
CEO, ALX Oncology
Board Member
early stage
11 investments
2015
Mid stage· 1
?
Board Member
mid stage
Feb 2020
Investor geography1 country
United States
1
Frequently asked questions
Who invested in ALX Oncology?
ALX Oncology has 2 investors on record on gritt.io, including 1 early-stage backers, 1 mid-stage.
When did ALX Oncology last raise funding?
The most recent investment in ALX Oncology recorded on gritt.io was in February 2020.
When was ALX Oncology founded?
ALX Oncology was founded in 2015.
What industry is ALX Oncology in?
ALX Oncology operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is ALX Oncology based?
ALX Oncology is headquartered in South San Francisco, United States.